HONG KONG -- Vivo Capital, a global health care investment company that has backed Chinese companies such as medical-tech platform WuXi AppTec, has held the first closing of a new yuan-denominated fund at 4 billion yuan ($600 million), with a target of eventually raising about 10 billion yuan.
DealStreetAsia
U.S. equity firm closes yuan-fund eyeing Chinese medical sector
Vivo Capital seeks to invest in drug R&D and health care technology
Vivo Capital's portfolio companies include WuXi AppTec, one of Asia's largest pharmaceutical R&D platforms. (Captured images from Wuxiapptec and Vivo Capital website)
Read Next
Latest on DealStreetAsia
